 SANTA MONICA, Calif., July 06, 2021 GLOBE NEWSWIRE -- Opiant Pharmaceuticals, Inc. Opiant NASDAQ: OPNT today announced positive top-line results from its confirmatory pharmacokinetic PK study for OPNT003, nasal nalmefene, for opioid overdose. 